Prosecution Insights
Last updated: April 19, 2026

Neurocrine Biosciences Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
3
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18705079 VALBENAZINE COMPOSITIONS LIU, TRACY 1614 Non-Final OA Apr 26, 2024
18286935 METHODS FOR THE COMBINED ADMINISTRATION OF DEUTETRABENAZINE AND A CYP2D6 INHIBITOR NESTOR, DONNA MICHELLE 1627 Non-Final OA Oct 13, 2023
18286944 METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS NESTOR, DONNA MICHELLE 1627 Non-Final OA Oct 13, 2023
18042748 CRF RECEPTOR ANTAGONISTS AND METHODS OF USE HASTINGS, ALISON AZAR 1627 Final Rejection Feb 23, 2023
17797368 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE WILSON, JERICA KATLYNN 1621 Final Rejection Aug 03, 2022
16105396 Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis RODRIGUEZ, RAYNA B 1628 Final Rejection Aug 20, 2018

Managing Neurocrine Biosciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month